May 27, 2025
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
May 27, 2025
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing RequirementVIEW RELEASE
May 12, 2025
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Jun 06, 2025 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.84
CHANGE
0.31 (20.26%)
